AMERICAN JURNAL OF ADVANCED SCIENTIFIC RESEARCH
ISSN 2195-1381 Volume- 4 May 2025
https://journal-index.org/index.php/ajasr

RISK FACTORS FOR KIDNEY DAMAGE IN OSTEOPOROSIS WITH HEART FAILURE

Nadirova Yulduz Isom qizi

Bobosharipov Feruz Gofurjonovich

Xolov Husniddin Omonollaevich

Uzbekistan. Tashkent. Tashkent medical Academy

Abstract: Recent studies have demonstrated a high risk of kidney damage and associated cardiovascular complications in patients with Osteoporosis which generally determines the prognosis of these patients. However, the frequency of chronic kidney disease (CKD) in Osteoporosis in the Uzbekistan cohort of patients has not been precisely established. The unfavorable prognostic significance of kidney damage in rheumatoid arthritis (RA) has been actively attracting the attention of researchers in recent years. Certain clinical variants of involvement of the kidneys in the pathological process in rheumatoid arthritis are noted in most patients. Various variants of kidney damage in rheumatoid arthritis are described, in particular, glomerulonephritis, amyloidosis, vasculitis, as well as iatrogenic forms (analgesic tubulopathy, membranous nephropathy, etc.). It is noteworthy that in real clinical conditions, morphological verification of renal pathology may not be performed for a long time in such patients for a number of objective reasons. Early manifestations of functional renal disorders, especially with their moderate severity, do not always attract the attention of clinicians, while the progression of chronic kidney disease (CKD) in Osteoporosis can be Osteoporosis, especially in old age, as well as in association with cardiovascular pathology. The formation of nephropathy in Osteoporosis has a complex multifactorial character and manifests itself in various clinical and morphological variants. Thus, various clinical forms of kidney damage in Osteoporosis are known (amyloidosis, glomerulonephritis, less often rheumatoid granulomatosis and rheumatoid renal vasculitis), as well as iatrogenic, due to ongoing treatment (medicinal tubulointerstitial nephritis, membranous nephropathy, mesangioproliferative glomerulonephritis). At the same time, in real clinical practice, the nosological diagnosis of kidney disease in Osteoporosis is usually established when clinical and laboratory criteria appear, the most important of which is proteinuria, at the same time, it has recently been established that with a low-symptomatic course, renal dysfunction can develop without the presence of proteinuria. It is noteworthy that rheumatologists do not always pay attention to the early manifestations of functional renal disorders, especially with moderate severity of proteinuria, although the Osteoporosiste of decline in kidney function in

Osteoporosis can be quite fast, especially in old age and in association with cardiovascular pathology.

Keywords: osteoporosis, kidney damage, chronic kidney disease, genetically engineered drugs

Introduction:

Osteoporosis is an autoimmune disease characterized by the development of chronic destructive polyarthritis with frequent involvement of other systems in the pathological process. Extraarticular systemic lesions in Osteoporosis can have a serious impact on the prognosis of the disease. Major studies conducted in recent years have demonstrated the association Osteoporosis at high risk of chronic kidney disease (CKD) and cardiovascular complications, which is associated with an increase in mortality in this category of patients. In the Russian population, studies devoted to this problem are still few. The spectrum of renal pathology underlying CKD in Osteoporosis is quite wide. Secondary amyloidosis for many years occupied the main position among the variants of nephropathy in Osteoporosis patients. According to some studies, there is a tendency to change the structure of kidney damage in Osteoporosis, taking into account the use of highly effective therapy regimens, including genetically engineered drugs, which serves as an additional prerequisite for studying this category of patients. It is very important that according to modern concepts, functional renal disorders lasting more than three months (so-called chronic kidney disease), including without a definite nosological diagnosis, are considered as the most important prognostic factor requiring correction of therapeutic tactics both in the general population and, possibly, in Osteoporosis. According to some researchers, the development of chronic kidney disease in Osteoporosis may be associated with cardiovascular pathology, while renal pathology itself is a risk factor for damage to the cardiovascular system. At the same time, no large-scale epidemiological studies have been conducted on the prevalence of chronic kidney disease in Osteoporosis and risk factors associated with its development, and the available data are scattered and contradictory. Thus, the assessment of functional renal disorders and associated factors in Osteoporosis is relevant for clinical medical practice, approaches to early detection of renal pathology and assessment of the risk of its progression in Osteoporosis are insufficiently developed. In recent years, much attention has been paid by researchers to cardiorenal relationships. The results of epidemiological and population studies indicate that even the earliest subclinical renal dysfunction are independent risk factors for cardiovascular events and death. A decrease in glomerular filtration Osteoporosiste (GFR) and an increase in urinary albumin

excretion are currently considered as "renal" markers of an unfavorable prognosis within the cardiorenal continuum. Thus, the attention of clinicians is focused primarily on the defeat of the glomerular apparatus of the kidney. However, in recent years, there has been more and more data on the importance of assessing the condition and tubulointerstitial kidney tissue, which, according to a number of researchers, is involved in the pathological process in cardiovascular diseases often before the glomerular apparatus The aim of the study was to establish the frequency of kidney damage, as well as clinical and morphological variants and risk factors for the development of secondary nephropathy in Osteoporosis patients.

Materials And Methods

A retrospective analysis of the medical histories of Osteoporosis patients was carried out. For the diagnosis of Osteoporosis, the classification criteria ACR/EULAR 2010 (American College of Rheumatology/European League Against Rheumatism Rheumatoid arthritis classification criteria). The following indicators were evaluated in all examined patients: age, gender, duration of the disease, the presence of signs of kidney damage, as well as any other extra-articular manifestations of the disease (lung, skin, blood system damage etc.), serological variant of the disease (seropositive or seronegative), as well as clinical and laboratory indicators of Osteoporosis activity, in particular ESR, C-reactive protein (CRP), hemoglobin and the DAS28-ESR index. The indicators of lipid and carbohydrate metabolism, body mass index, presence and degree of arterial hypertension (AH) were evaluated from the general population risk factors for CKD. Diagnosis CKD was established in accordance with the KDIGO criteria of 2010: 1) identification of any clinical markers of kidney damage confirmed over a period of at least 3 months; 2) the presence of structural changes in the kidneys revealed during the lifetime morphological examination of the organ; 3) decrease in glomerular filtration Osteoporosiste (GFR)

Biopsy material of kidney tissue and rectal mucosa was studied at the light-optical level, and an immunofluorescence study was also conducted. The presence of amyloid in the tissues of the kidney and rectal mucosa was confirmed on the basis of coloring with Congo red dye with microscopy in polarized light. Statistical data analysis was carried out using the software packages Statistica 10.0 and SPSS 22. Median and interquartile Osteoporosisnge were evaluated. When comparing groups with and without kidney damage, the nonparametric Mann–Whitney criterion was used. Spearman's nonparametric Osteoporosisnk correlation method and multivariate linear regression analysis are used to identify and evaluate the relationships between the studied indicators. Results And Discussion The incidence

of CKD in Osteoporosis patients was 19.7% (41 out of 104) among patients observed in the 1st Clinic of TMA in the period 2018-2019. Among 90 persons included in the study, 78 (86.7%) were women and 12 (13.3%) were men, the Osteoporosistio was 7:1. The average age of all patients was 58.3 [50.5; 69.5] years. Various clinical and laboratory variants of kidney damage were observed in 43 out of 90 patients. According to the KDIGO criteria, CKD of stages I–II is noted in 13 (29.1%) out of 43 patients, stage III–IV CKD – in 31 (70.9%) out of 43. To assess the morphological variants of kidney damage in Osteoporosis, the results of a study of 13 kidney biopsies and 5 biopsies of the rectal mucosa are available, and in 4 the clinical picture of renal damage most corresponded to tubulointerstitial nephritis, therefore, the nosological variant of kidney damage was determined in 23 cases. In 12 (50.0%) of 24 patients, a picture of renal amyloidosis was revealed (in 6 cases – by kidney biopsy, 6 – by biopsy of the rectal mucosa). 7 (30.4%) of 24 patients had chronic glomerulonephritis (CGN), while proliferative forms prevailed: mesangioproliferative glomerulonephritis (GN) – in 3 patients, membranoproliferative GN – in 1 patient. The picture of membranous nephropathy and the disease of minimal changes – in 1 case. Isolated proteinuria was observed in 4 patients, and an isolated decrease in GFR0.05), the degree of eGFR reduction (61 [32-78] ml/min vs 55 [37-77] ml/min; p>0.05), as well as the severity of nephrotic syndrome (albumin 32.1 [26.2– 39.1] g/l vs 34.5 [28.8–40.9] g/l; p>0.05) in the groups of patients with renal amyloidosis and CGN, there were no significant differences, however, in the group of patients with renal amyloidosis were the duration of the disease and the level of CRP are significantly higher. Among the 90 analyzed patients, 62 received basic therapy with methotrexate or leflunomide, 14 received genetically engineered drugs: rituximab, abatacept, tumor necrosis factor α (TNF–α) inhibitors - infliximab, etanercept, golimumab, certolizumab pegol, adalimumab, interleukin-6 –tocilizumab inhibitors, kinase inhibitor - tofacitinib; 13 – various combinations of corticosteroids, sulfasalazine and hydroxychloroquine. We did not note significant differences in the level of proteinuria (0 [0-0.68] g/day vs 0 [0-0.72] g/day; p>0.05) and eGFR (74 [59-87] ml/min vs 59 [47-80] ml/min; p>0.05) in groups of patients receiving treatment with biological genetically engineered drugs and basic therapy with methotrexate or leflunomide, respectively. CKD in RA with older age, hypertension, as well as disorders of lipid and carbohydrate metabolism. In addition, according to our data, the most significant independent risk factor was the duration of the disease, the influence of seropositivity for rheumatoid factor, the presence of other systemic manifestations was also noted. RA, high ESR, CRP and the DAS28 index, which indicates a great importance of inflammatory activity RA in the development of CKD. The importance of long-term persistence of chronic inflammation in the development of

CKD in RA in recent years has been given much attention in the world literature. So, in the work of M. Kochi et al. Elevated CRP levels for at least 6 months were an independent risk factor for CKD. In population studies It was found that a high level of inflammatory markers interleukin-6 and TNF-α is also a predictor of deterioration of kidney function in RA. Chronic inflammation can directly affect the development of tubulointerstitial fibrosis through the deposit of CRP in the glomerular endothelium and tubular epithelium. An increase in CRP in transgenic mice causes severe inflammation with infiltration of tubulointerstition by T-lymphocytes and macrophages. It was found that an increased level of CRP may be associated with endothelial dysfunction in RA patients, causing damage to afferent arterioles and intraclubular hypertension. So, the vast majority of RA patients (60out of 66) had nephrosclerosis, which the authors associated with hypertension, however, the presence of a correlation between the degree of nephrosclerosis and the duration of RA suggested that the activity of RA can directly affect the development of fibrous changes in the kidney. The diagnosis of nephropathy in RA is most often established on the basis of the appearance of proteinuria, but a decrease in GFR can be detected in the absence of proteinuria. We The high frequency of isolated GFR reduction (36.0%) in RA patients was also confirmed. The decrease in GFR may be due to prolonged use of nonsteroidal anti-inflammatory drugs. So, B. Möller et al. it was established that nonsteroidal anti-inflammatory drugs are an independent factor of progression CKD and GFR reduction

Conclusion

In recent years, the role of genetically engineered biological agents in reducing not only cardiovascular risk, but also the frequency of CKD in Osteoporosis patients has been discussed. The beneficial effects of biological agents on endothelial function , lipid metabolism and insulin resistance can directly (by interrupting inflammation and endothelial dysfunction) and indirectly (through changes in lipid metabolism, carbohydrates, etc.) affect the risk of developing CKD in this patient population. We also assessed the impact of genetic engineering However, there were no statistically significant differences in patients receiving treatment with traditional basic drugs (methotrexate and/or leflunomide) or genetically engineered drugs in our sample. On the contrary, according to K. Immonen et al., new basic drugs, including biological targeted agents, are more effective in suppressing systemic inflammation, and the use of these drugs reduces the frequency of the development of amyloidosis . Currently, there are several studies that indicate the effectiveness of TNF-α inhibitors in improving kidney function in patients withOsteoporosis and amyloidosis. K. Sumida et al. in a large number of patients withOsteoporosis (20,757 patients), it was shown that the administration of biological drugs significantly slows

down the development and progression of CKD. The lack of a clear link between CKD and therapy in our study may be due to insufficient follow-up and a small number of patients in the study sample. Prospective studies are needed to assess the degree of decrease in renal function in dynamics during treatment.

Literature:

1. Mirzaeva, G. P., Yu, N., Buvamukhamedova, N. T., & Mukhiddinova, F. M. (2023). Evaluation of the effectiveness of antioxidants on the functional state of the kidneys in patients with diabetic nephropathy. *The Journal of clinical investigation*, 12-23.
2. Бобошарипов, Ф. Г., Холов, Х. А., Тешаев, О. Р., & Надирова, Ю. И. (2023). ПОСТБАРИАТРИЧЕСКАЯ ГИПОГЛИКЕМИЯ И ГИПОТОНИЯ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *21*(5), 105-113.
3. Надирова, Ю. И., Жаббаров, О. О., Бобошарипов, Ф. Г., Турсунова, Л. Д., & Мирзаева, Г. П. (2023). Оценка эффективности и оптимизация дезаггрегантной терапии у больных с ИБС.
4. Холов, Х. А., Тешаев, О. Р., Бобошарипов, Ф. Г., Амонуллаев, А. Х., & Надирова, Ю. И. (2023). ОСТРЫЙ ПАНКРЕАТИТ-КАК НЕРЕШЕННАЯ ПРОБЛЕМА МЕДИЦИНЫ. *Академические исследования в современной науке*, *2*(8), 192-206.
5. Бобошарипов, Ф. Г., Холов, Х. А., Тешаев, О. Р., Алимов, С. У., & Надирова, Ю. И. (2023). ОСЛОЖНЕНИЕ ОСТРОГО ХОЛЕЦИСТИТА У БОЛЬНЫХ ПЕРЕНЯВШИСЬ COVID-19. In *Международная конференция академических наук* (Vol. 2, No. 3, pp. 41-48).
6. Бобошарипов, Ф. Г., Холов, Х. А., Тешаев, О. Р., Алимов, С. У., & Надирова, Ю. И. (2023). КОМОРБИДНОЕ ТЕЧЕНИЕ ОСТРОГО ХОЛЕЦИСТИТА У БОЛЬНЫХ COVID-19. *Models and methods in modern science*, *2*(4), 51-58.
7. Bobosharipov, F. G., Xolov, X. A., & Yu, N. (2024). ACUTE PANCREATITIS AFTER ELECTIVE LAPAROSCOPIC CHOLECYSTECTOMY: RETROSPECTIVE STUDY. In *Proceedings of Scientific Conference on Multidisciplinary Studies* (Vol. 3, No. 6, pp. 132-136).
8. Bobosharipov, F. G., Ruxullayevich, T. O., Amonullayevich, X. X., & Isomovna, N. Y. (2024). GENETIC INFLUENCES FOR PEPTIC ULCER DISEASE ARE INDEPENDENT OF GENETIC FACTORS IMPORTANT FOR HP INFECTION.

9. Надирова, Ю. И., & Бобошарипов, Ф. Г. (2024). Клинико-диагностические аспекты раннего развития остеопороза при хронической сердечной недостаточности.
10. Бобошарипов, Ф. Г., Надирова, Ю. И., & Алимов, С. У. (2024). ЛЕТАЛЬНОСТЬ ПОСЛЕ КОНСЕРВАТИВНОГО ЛЕЧЕНИЕ ПРИ ЯЗВЕННЫХ ГАСТРОДУОДЕНАЛЬНЫХ КРОВОТЕЧЕНИЯХ.
11. Надирова, Ю. И., Бобошарипов, Ф. Г., Кодирова, Ш. А., & Мирзаева, Г. П. (2023). ОСТЕОПОРОЗ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *21*(5), 89-96.
12. GP, M., OO, J., ZF, U., Sh I, Q., LD, T., Yu I, N., & AM, R. (2023). Assessment of Efficacy and Optimization of Antiplatelet Therapy in Patients with Ischemic Heart Disease.
13. Надирова, Ю., & Жаббаров, О. (2023). ФАКТОРЫ РИСКА СНИЖЕНИЯ ПРОЧНОСТИ КОСТИ И ПЕРЕЛОМОВ ПРИ ХБП.
14. Надирова, Ю. И., & Нуриллаева, Н. М. (2019). РОЛЬ ГЕНЕТИЧЕСКОГО ПОЛИМОРФИЗМА ГЕНА MTHFR С РИСКОМ РАЗВИТИЯ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА. In *Современная медицина: новые подходы и актуальные исследования* (pp. 20-23).
15. Холов, Х. А., Бобошарипов, Ф. Г., & Надирова, Ю. И. К. (2016). Оптимизация диагностики острого панкреатита. *Биология и интегративная медицина*, (6), 150-159.
16. Nadirova, Y. (2024). SURUNKALI YURAK YETISHMOVCHILIGIDA OSTEOPOROZ ETIOLOGIYASIGA KO ‘RA XUSUSIYATLARI. *Инновационные исследования в современном мире: теория и практика*, *3*(13), 35-38.
17. Надирова, Ю. И., & Жаббаров, О. О. (2024). КОСТНАЯ ПАТОЛОГИЯ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК. *Инновационные исследования в современном мире: теория и практика*, *3*(13), 31-34.
18. Bobosharipov, F. (2025). OSTEOPATHY IN CHRONIC KIDNEY DISEASE. *Академические исследования в современной науке*, *4*(23), 25-28.
19. Bobosharipov, F., & Nadirova, Y. (2025). ЛАПАРОСКОПИК УСУЛДА ГАСТРОДУОДЕНАЛ ЯРАЛАРНИНГ ПЕРФОРАЦИЯСИНИ ТИКИШ. *Наука и инновация*, *3*(14), 4-6.
20. Надирова, Ю. (2024). ЭФФЕКТИВНОСТЬ ПРИМЕНЕНИЯ СТАТИНОВ ПРИ ЛЕЧЕНИИ ОСТЕОПОРОЗА. *Академические исследования в современной науке*, *3*(46), 96-100.

21. Исмоилов, И. М., Надирова, Ю. И., Рахматуллаева, Н. Т., Мадазимова, Д. Х., & Назарова, Н. О. (2020). АГРЕГАЦИОННАЯ ФУНКЦИЯ ТРОМБОЦИТОВ ПРИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ. *Студенческий вестник*, (24-2), 65-66.
22. Аьзамхонов, А. А., Насриддинова, Н. Н., Максудова, М. Х., & Надирова, Ю. И. (2020). ИЗУЧЕНИЕ АСПЕКТОВ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА, ОСЛОЖНЕННОЙ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ. *Студенческий вестник*, (3-2), 66-67.
23. Абдунабиев, Х. А., Насриддинова, Н. Н., Максудова, М. Х., & Надирова, Ю. И. (2020). ЭФФЕКТИВНОСТЬ САКУБИТРИЛ/ВАЛСАРТАНА У БОЛЬНЫХ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ, ОСЛОЖНЕННОЙ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ. *Студенческий вестник*, (3-2), 64-65.
24. Каримов, А. А., Сайдалиев, Р. С., & Надирова, Ю. И. (2020). ВЛИЯНИЯ ПРИМЕНЕНИЯ САКУБИТРИЛ/ВАЛСАРТАН У БОЛЬНЫХ ХСН. In *ИННОВАЦИОННЫЕ ПОДХОДЫ В СОВРЕМЕННОЙ НАУКЕ* (pp. 14-18).
25. Nadirova, Y. I., Jabbarov, O. O., & Bobosharipov, F. G. CARDIAC AND RENAL DISEASES OFTEN COEXIST AND PATIENTS WITH CARDIAC AND RENAL FAILURE HAVE HIGH MORBIDITY.